Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Summary

Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.

Interventions

• BPI-572270 · DRUG

  Oral Tablets

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Histologically confirmed advanced solid tumor with RAS mutations identified through deoxyribonucleic acid (DNA) sequencing.
* Have received prior standard therapy appropriate for tumor type and stage.
* Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Adequate organ function.

Exclusion Criteria:

* Primary central nervous system (CNS) tumors active and untreated brain metastases.
* Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication.
* History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy

Sites (7)

• Blacktown Hospital, Blacktown, New South Wales · Not yet recruiting
• Scientia Clinical Research, Randwick, New South Wales · Not yet recruiting
• GenesisCare St Leonards, 7 Westbourne St, St Leonards, Sydney, New South Wales · Not yet recruiting
• Southern Oncology Clinical Research Unit (SOCRU), Bedford Park, South Australia · Not yet recruiting
• Warringal Private Hospital, Heidelberg, Victoria · Not yet recruiting
• Linear Clinical Research Ltd, Nedlands, Western Australia · Not yet recruiting
• Zhejiang Cancer Hospital, Hangzhou, Zhejiang · Recruiting